we are 10% ANP

ANP's ATL1103 Acromegaly Phase II Clinical Trial will complete this week.
24 patients have completed the full 13 weeks of dosing in the trial. The opportunity presented for the Company to enrol an additional 2 acromegalic patients into the trial (now 26 in total) who will receive their final dose of ATL1103 by 19 July 2014, which will mark the completion of all dosing in the trial.